Skip to content
Review Open access

Primary resistance to afatinib in a patient with NSCLC harboring EGFR p.E709_T710delinsD and brain metastases: a case report and literature review

Oct 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 33 references

TL;DR

It is suggested that in patients with high baseline disease burden and aggressive tumor biology, this variant may present as a phenotype with no initial benefit and rapid progression, and repeat biopsy or circulating tumor DNA testing should be pursued as soon as safely feasible to clarify the resistance mechanism and guide subsequent treatment.

Abstract

EGFR p.E709_T710delinsD is a rare in-frame deletion-insertion P-loop and alpha-C-helix compressing (PACC) mutation of EGFR exon 18. Current evidence suggests that patients with non-small cell lung cancer (NSCLC) harboring this variant generally respond to afatinib. However, primary resistance to afatinib in this molecular subset is rarely reported. We report a 68-year-old man diagnosed with stage IV lung adenocarcinoma harboring an EGFR p.E709_T710delinsD mutation (variant allele frequency, 45.9%) with co-occurring EGFR amplification (fold change 1.5). Brain metastases were present at baseline. The patient was treated with oral afatinib at an initial dose of 30 mg once daily but the disease progressed rapidly, suggesting possible primary targeted resistance. The patient died 5 weeks later. This case represents a rare example of primary resistance to afatinib in non-small cell lung cancer (NSCLC) harboring the EGFR p.E709_T710delinsD mutation. Given the lack of tissue and molecular evidence to confirm the resistance mechanism in this case, this report combines previous literature to explore the potential factors associated with treatment failure and their clinical implications. This case does not refute the overall sensitivity of this variant to afatinib, but suggests that in patients with high baseline disease burden and aggressive tumor biology, this variant may present as a phenotype with no initial benefit and rapid progression. For such rapidly progressive cases, early radiographic reassessment should be performed, and repeat biopsy or circulating tumor DNA (ctDNA) testing should be pursued as soon as safely feasible to clarify the resistance mechanism and guide subsequent treatment.

Read PDF

Similar papers

Case report Open access Oct 2026

Early disease control with a biochemical response to aumolertinib after postoperative recurrence of EGFR-Mutant stage IIIA lung adenocarcinoma after icotinib, with EGFR T790M detected at recurrence: a Case Report

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are a standard treatment for EGFR-mutant non-small cell lung cancer (NSCLC). However, acquired resistance commonly develops after treatment with first- or second-generation EGFR-TKIs. Aumolertinib, a third-generation EGFR-TKI, has demons...

Zhen-Yu Niu, Yi-Juan-Qian Zhu, Yu Zhou et al. · 0 citations
Case report Open access Oct 2026

Case Report: Coexpression of somatic EGFR, BRCA1, and BRCA2 mutations in metastatic non-small cell lung cancer

Background Treatment of non-small cell lung cancer (NSCLC) has evolved dramatically over the past decade with the advent of widespread genetic testing, immunotherapy, and targeted therapies. Treatments directed against epidermal growth factor receptor (EGFR) and other driver mutations have reduced toxicity and improved...

Aaron Negin, Kush Sachdeva, J. Weiss · 0 citations
Case report Open access Oct 2026

Simultaneous occurrence of HER2 mutation and PD-L1 high expression in EGFR-mutant NSCLC: a case report

In non-small cell lung cancer (NSCLC), EGFR and HER2 mutations are generally considered mutually exclusive events, with a co-occurrence probability estimated to be less than 1%. Patients with either EGFR or HER2 mutations tend to exhibit low PD-L1 expression levels. The simultaneous presence of both EGFR and HER2 mutat...

Yun-Xia Su, Huan-Zhang Su, Jian-Guang Lin · 0 citations
Case report Open access Sep 2026

Case Report: Dramatic response of trastuzumab rezetecan in an NSCLC patient with EGFR sensitive mutation and primary ERBB2 genetic alterations

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have provided significant clinical benefit to patients with EGFR-mutant non-small cell lung cancer (NSCLC), but multiple concurrent genetic alterations may limit their efficacy. We report a case of advanced lung adenocarcinoma harboring concurrent...

Lin Zhang, Chuan-Tao Zhang, Hui-Yun Wang et al. · 0 citations
Open access Sep 2026

A first case report of recurrent gastric cancer harboring a BRAFV600E mutation responding to dabrafenib plus trametinib

Comprehensive genomic profiling (CGP) has been increasingly implemented in clinical practice; however, only a limited proportion of patients ultimately receive genomically matched therapies. The BRAF V600E mutation is extremely rare in gastric cancer, and effective targeted treatment strategies remain undefined....

Shunsuke Kagawa, Yoshihiko Kakiuchi, Hideki Yamamoto et al. · 0 citations
Oct 2026

Firmonertinib 160mg in EGFR-Mutated NSCLC with Brain Metastases After EGFR-TKI Resistance (iFORCE): Clinical Outcomes and Mechanistic Insights.

BACKGROUND Brain metastases (BM) are frequent in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) and remain challenging after prior EGFR tyrosine kinase inhibitor (TKI) therapy. This exploratory study evaluated high-dose fimmonertinib and explored subtype-specific spatial biology. METHODS iFORCE was a prospec...

M. You, Tong-Ji Xie, Li-Ge Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.